BioStem Technologies Inc., a leading regenerative medicine company, announced that company management will present at the 25th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Monday, April 13, 2026, at 8:45 am ET, with live and archived webcasts available on the company's investor relations website at https://ir.biostemtechnologies.com.
The conference presentation provides BioStem with a platform to showcase its portfolio of perinatal tissue allograft products to healthcare investors and industry stakeholders. The company specializes in developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue, leveraging proprietary processing technologies including BioRetain®, CryoTek® and SteriTek®. These technologies are designed to optimize the preservation of natural tissue properties, supporting clinical applications across various medical specialties.
BioStem's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks and comply with current Good Tissue Practices and current Good Manufacturing Processes. The company's product portfolio includes the Neox®, Clarix®, VENDAJE® and American Amnion™ product lines, which are used by clinicians nationwide. For more information about the company's products and technologies, visit https://biostemtechnologies.com.
The presentation at this prominent healthcare investment conference signals BioStem's continued growth and innovation in the regenerative medicine sector. As a publicly traded company under the ticker symbol BSEM, BioStem maintains expanding clinical research initiatives and a national commercial footprint. The company's focus on perinatal tissue allografts represents a significant segment of the regenerative medicine market, which continues to evolve with advancements in tissue preservation and clinical applications.
For investors and industry observers, BioStem's participation in the Needham conference offers insights into the company's strategic direction, product development pipeline, and market positioning. The regenerative medicine field has gained increasing attention for its potential to address complex medical conditions through biological solutions rather than traditional pharmaceuticals or medical devices. BioStem's proprietary processing technologies and AATB-accredited quality systems position the company within this growing sector, where regulatory compliance and clinical efficacy are paramount considerations for healthcare providers and patients alike.
The latest news and updates relating to BioStem Technologies are available in the company's newsroom at https://tinyurl.com/bsemnewsroom. The Needham Virtual Healthcare Conference brings together leading healthcare companies and investors, providing a forum for discussing innovations, market trends, and investment opportunities in the healthcare sector.
